SARS-CoV-2 mRNA Vaccines: Immunological Mechanism and Beyond

To successfully protect against pathogen infection, a vaccine must elicit efficient adaptive immunity, including B and T cell responses. While B cell responses are key, as they can mediate antibody-dependent protection, T cells can modulate B cell activity and directly contribute to the elimination...

Full description

Bibliographic Details
Published in:	Vaccines
Main Authors:	Emily Bettini, Michela Locci
Format:	Article
Language:	English
Published:	MDPI AG 2021-02-01
Subjects:	SARS-CoV-2 coronavirus mRNA vaccines adaptive immunity antibodies germinal centers
Online Access:	https://www.mdpi.com/2076-393X/9/2/147

Similar Items

Development of Bivalent mRNA Vaccines against SARS-CoV-2 Variants
by: Jianglong Li, et al.
Published: (2022-10-01)

Can Individuals with Suboptimal Antibody Responses to Conventional Antiviral Vaccines Acquire Adequate Antibodies from SARS-CoV-2 mRNA Vaccination?
by: Wataru Ogura, et al.
Published: (2022-05-01)

mRNA technology as one of the promising platforms for the SARS-CoV-2 vaccine development
by: A. A. Ilyichev, et al.
Published: (2020-12-01)

Circulating Antibodies Against Common Cold Coronaviruses Do Not Interfere with Immune Responses to Primary or Booster SARS-CoV-2 mRNA Vaccines
by: Bindu Adhikari, et al.
Published: (2025-05-01)

MERS-CoV RBD-mRNA vaccine induces potent and broadly neutralizing antibodies with protection against MERS-CoV infection
by: Wanbo Tai, et al.
Published: (2023-09-01)

The Screening of Broadly Neutralizing Antibodies Targeting the SARS-CoV-2 Spike Protein by mRNA Immunization in Mice
by: Zhiyin An, et al.
Published: (2023-05-01)

Kinetics of the Neutralizing and Spike SARS-CoV-2 Antibodies following the Sinovac Inactivated Virus Vaccine Compared to the Pfizer mRNA Vaccine in Singapore
by: Chin Shern Lau, et al.
Published: (2022-05-01)

Robust SARS-CoV-2 Antibody Responses in Asian COVID-Naïve Subjects 180 Days after Two Doses of BNT162b2 mRNA COVID-19 Vaccine
by: Chin-Shern Lau, et al.
Published: (2021-10-01)

Immunogenicity of SARS-CoV-2 mRNA Vaccine in Breast Cancer Patients Undergoing Active Treatment: A Prospective Observational Study
by: María Leonor Fernández-Murga, et al.
Published: (2025-09-01)

Development of an LNP-Encapsulated mRNA-RBD Vaccine against SARS-CoV-2 and Its Variants
by: Cong Liu, et al.
Published: (2022-05-01)

Clustering Analysis Identified Distinct Clinical Phenotypes among Hemodialysis Patients in Their Immunological Response to the BNT162b2 mRNA Vaccine against SARS-CoV-2
by: Guy Rostoker, et al.
Published: (2024-10-01)

Comparison of anti-phospholipid antibody titers before and after SARS-CoV-2 mRNA vaccination in hospital staff
by: Michi Hisano, et al.
Published: (2024-10-01)

Impact of SARS-CoV-2 mRNA vaccine on arthritis condition in rheumatoid arthritis
by: Ayuko Takatani, et al.
Published: (2023-08-01)

Analysis of B-cell receptor repertoire to evaluate the immunogenicity of SARS-CoV-2 RBD mRNA vaccine: MAFB-7256a (DS-5670d)
by: Goh Ohji, et al.
Published: (2024-10-01)

Evolution of SARS-CoV-2 antibody repertoire after successive mRNA vaccinations under immunosuppressive treatmentResearch in context
by: Jim B.D. Keijser, et al.
Published: (2025-03-01)

Design and preclinical evaluation of a universal SARS-CoV-2 mRNA vaccine
by: Jane Qin, et al.
Published: (2023-03-01)

A novel mRNA vaccine, SYS6006, against SARS-CoV-2
by: Ke Xu, et al.
Published: (2023-01-01)

Analysis of Neutralization Titers against SARS-CoV-2 in Health-Care Workers Vaccinated with Prime-Boost mRNA–mRNA or Vector–mRNA COVID-19 Vaccines
by: Christina Sølund, et al.
Published: (2022-01-01)

Delivery of mRNA Vaccine against SARS-CoV-2 Using a Polyglucin:Spermidine Conjugate
by: Larisa I. Karpenko, et al.
Published: (2021-01-01)

Safety and immunogenicity of a SARS-CoV-2 mRNA vaccine (SYS6006) in minks, cats, blue foxes, and raccoon dogs
by: Hong Huo, et al.
Published: (2024-09-01)

Association between sleep duration and antibody acquisition after mRNA vaccination against SARS-CoV-2
by: Muneto Izuhara, et al.
Published: (2023-12-01)

Advancements in mRNA Encoded Antibodies for Passive Immunotherapy
by: Cailin E. Deal, et al.
Published: (2021-01-01)

HLA Class II Polymorphism and Humoral Immunity Induced by the SARS-CoV-2 mRNA-1273 Vaccine
by: Juan Francisco Gutiérrez-Bautista, et al.
Published: (2022-03-01)

SARS-CoV-2 RBD Scaffolded by AP205 or TIP60 Nanoparticles and Delivered as mRNA Elicits Robust Neutralizing Antibody Responses
by: Johnathan D. Guest, et al.
Published: (2025-07-01)

Mechanism of modified mRNA structure in COVID-19 vaccines for inducing neutralizing antibodies
by: Sabighoh Zanjabila, et al.
Published: (2024-10-01)

SARS-CoV-2 mRNA vaccination induces an intranasal mucosal response characterized by neutralizing antibodies
by: Kevin T. Cao, BS, et al.
Published: (2023-11-01)

SARS-CoV-2 Antibody Dynamics in Healthcare Workers after mRNA Vaccination
by: Kevin D. Dieckhaus, et al.
Published: (2023-02-01)

Impact of Previous Common Human Coronavirus Exposure on SARS-CoV-2-Specific T-Cell and Memory B-Cell Response after mRNA-Based Vaccination
by: José L. Casado, et al.
Published: (2023-02-01)

Review of Ribosome Interactions with SARS-CoV-2 and COVID-19 mRNA Vaccine
by: Jiao Wei, et al.
Published: (2022-01-01)

Antibody Response Induced by BNT162b2 and mRNA-1273 Vaccines against the SARS-CoV-2 in a Cohort of Healthcare Workers
by: Juan F. Delgado, et al.
Published: (2022-06-01)

Decreased and Heterogeneous Neutralizing Antibody Responses Against RBD of SARS-CoV-2 Variants After mRNA Vaccination
by: Pablo Hernández-Luis, et al.
Published: (2022-04-01)

Immunogenicity of the Two mRNA SARS-CoV-2 Vaccines in a Large Cohort of Dialysis Patients
by: Paraskevi Tsoutsoura, et al.
Published: (2022-11-01)

Impact of Low-Dose Methotrexate–Adalimumab Combination Therapy on the Antibody Response Induced by the mRNA-1273 SARS-CoV-2 Vaccine: Case of an Elderly Patient with Rheumatoid Arthritis
by: Yves Michiels, et al.
Published: (2021-08-01)

Challenges and Scientific Prospects of the Newest Generation of mRNA-Based Vaccines against SARS-CoV-2
by: Daniela Calina, et al.
Published: (2021-08-01)

Mechanisms and research advances in mRNA antibody drug-mediated passive immunotherapy
by: Yuxiang Zhao, et al.
Published: (2023-10-01)

SARS-CoV-2 Gamma and Delta Variants of Concern Might Undermine Neutralizing Activity Generated in Response to BNT162b2 mRNA Vaccination
by: Luigia Trabace, et al.
Published: (2022-04-01)

Large-Scale Study of Antibody Titer Decay following BNT162b2 mRNA Vaccine or SARS-CoV-2 Infection
by: Ariel Israel, et al.
Published: (2021-12-01)

Anti-spike antibody responses to SARS-CoV-2 mRNA vaccines in people with schizophrenia and schizoaffective disorder
by: Katlyn Nemani, et al.
Published: (2024-07-01)

Heterologous vaccination with inactivated vaccine and mRNA vaccine augments antibodies against both spike and nucleocapsid proteins of SARS-CoV-2: a local study in Macao
by: Hoi Man Ng, et al.
Published: (2023-05-01)

Bioinformatics Designing and Molecular Modelling of a Universal mRNA Vaccine for SARS-CoV-2 Infection
by: Elijah Kolawole Oladipo, et al.
Published: (2022-12-01)